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Abstract
Synthetic glucocorticoids such as methylprednisolone are compounds of fundamental
interest to the pharmaceutical industry as their modifications within the sterane
scaffold lead to higher inflammatory potency and reduced side effects compared with
their parent compound cortisol. In methylprednisolone production, the complex
chemical hydroxylation of its precursor medrane in position C21 exhibits poor stereo‐
and regioselectivity making the process unprofitable and unsustainable. By contrast,
the use of a recombinant E. coli system has recently shown high suitability and
efficiency. In this study, we aim to overcome limitations in this biotechnological
medrane conversion yielding the essential methylprednisolone‐precursor premedrol
by optimizing the CYP21A2‐based whole‐cell system on a laboratory scale. We
successfully improved the whole‐cell process in terms of premedrol production by (a)
improving the electron supply to CYP21A2; here we use the N‐terminally truncated
version of the bovine NADPH‐dependent cytochrome P450 reductase (bCPR−27) and
coexpression of microsomal cytochrome b5; (b) enhancing substrate access to the
heme by modification of the CYP21A2 substrate access channel; and (c) circumvent-
ing substrate inhibition which is presumed to be the main limiting factor of the
presented system by developing an improved fed‐batch protocol. By overcoming the
presented limitations in whole‐cell biotransformation, we were able to achieve a
more than 100% improvement over the next best system under equal conditions
resulting in 691mg·L−1·d−1 premedrol.
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1 | INTRODUCTION
Synthetic glucocorticoids are often used as immunosuppressants or
for hormone replacement therapy compensating enzymatic disorders
or deficiencies to treat various diseases like rheumatoid arthritis
(Kadmiel & Cidlowski, 2013; McMaster & Ray, 2008). They are very
similar to physiologically produced steroids, whereas their structure
differs in additional functional groups such as hydroxy or methyl
groups. These changes in the steroid framework modify the
physiological properties such as solubility, skin or intestinal absorp-
tion, or steroid receptor affinity (Diederich et al., 2015). The latter
particularly influences the suitability of the active substance for
targeted medication, as natural glucocorticoids often cause
unwanted side effects that typically manifest themselves in hyper-
tension, hypokalemia, osteoporosis, and other symptoms (Henzen,
2003; Schäcke, 2002; Schäcke et al., 2004). These occur due to the
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high coaffinity of these glucocorticoidal ligands to the mineralocorti-
coid receptor (MR) causing an aldosterone‐like response (Farman &
Rafestin‐Oblin, 2017). Avoiding such side effects while increasing the
therapeutic effect of steroidal drugs is a realistic goal and is often
achieved by steroid modification. This can be illustrated particularly
well using the example of the synthetic glucocorticoid methylpredni-
solone, which exhibits reduced MR affinity and multiplied glucocor-
ticoid potency compared with its unmethylated derivative,
prednisolone. Methylprednisolone, also known as medrol, is applied
for the treatment of arthritis and other inflammatory diseases and
thus, highly appreciated by the pharmaceutical industry (Bavetta,
Bekhor, Shah, O’Day, & Nimni, 1962). The increasing demand of this
compound requires the development of production strategies, that
are aimed at achieving high‐product yields while maintaining the
cost‐effectiveness of the process. Besides that, there is a common
interest in reducing the ecological footprint to a minimum. The
synthesis of this compound is challenging since, in particular, the
introduction of a hydroxyl group in position C21 is a demanding step
and difficult to achieve by chemical methods. Such reactions often
require multistep processes involving the introduction of protective
groups and the use of toxic reagents such as halogens. In addition,
by‐products increase the total expenditure and thus reduce produc-
tion efficiency due to required purification by chromatographic
methods (Koechlin, Kritchevsky, & Gallagher, 1951). The replacement
of chemical by biotechnological processes has therefore aroused
interest in recent decades, as the latter are highly suitable for the
environmentally sustainable and economic production of pharma-
ceuticals. Bacterial fermentation for the production of pharmaceu-
ticals offers (a) the possibility to accumulate high amounts of biomass
by the use of simple and nontoxic raw materials, (b) a high‐yield
production of catalytically active enzymes and (c) the production of
whole cells acting as biocatalysts. The latter can be used for the
execution of regio‐ and stereospecific reactions under mild condi-
tions while the cells provide and regenerate expensive cofactors such
as NADPH (Bureik & Bernhardt, 2007). In particular, the use of
cytochrome P450 enzymes (P450) in optimized bacterial whole‐cell
systems shows high potential and suitability for pharmaceutical
production (Bernhardt, 2006; Urlacher & Girhard, 2012). Recently,
the C21 hydroxylation of medrane has been established in a
recombinant Escherichia coli (E. coli) whole‐cell system that enables
the CYP21A2‐mediated production of premedrol, the precursor of
methylprednisolone (Brixius‐Anderko, Schiffer, Hannemann, Janocha,
& Bernhardt, 2015). Although this system allows the production of
considerable quantities of this compound, there is still potential for
improvement by circumventing existing limitations of the CYP21A2‐
mediated conversion. Frequently observed bottlenecks of P450
systems include an insufficient electron delivery (Bernhardt &
Urlacher, 2014; Sagadin, Riehm, Milhim, Hutter, & Bernhardt,
2018), whose efficiency is dependent on the choice of redox partners
for bioconversion. Their suitability varies dependent on the respec-
tive P450 isoform. Additionally, there is evidence that the rate‐
limiting transfer of the second electron can be supported by an
alternative bypass‐pathway via cytochrome b5, affecting product
formation velocity and efficiency (Vergères & Waskell, 1995).
Another possible limitation that can occur in recombinant whole‐
cell biocatalysis is the molecular obstruction of substrate access to
the active site (Wade, Winn, Schlichting, & Sudarko, 2004), which can
be modulated by substitution of the relevant residues that cause
steric or polar constraints. There is also the possibility of the
substrate and product inhibition (Edwards, 1970; Lin et al., 2001),
caused by exposure of toxic substrates or complex‐formation of the
enzyme with the substrate or product at excessively high concentra-
tions, respectively. Here, we addressed all of these possible obstacles
and, thus, (a) improved the efficiency of electron supply by using the
modified natural redox partner bCPR−27 and the coexpression of
cytochrome b5, (b) improved substrate conversion by molecular
modification of the substrate access channel, and (c) bypassed
substrate or product inhibition by performing fed‐batch cultivation of
E. coli.
2 | MATERIALS AND METHODS
2.1 | Chemicals and enzymes
Medrane and premedrol were obtained from Sanofi, Frankfurt‐
Höchst (DE) and of highest purity. Restriction enzymes were
obtained from New England Biolabs (Ipswich, MA) and Fast‐Link™
Ligase was purchased from Lucigen Corporation. The PCRs were
performed with Phusion® High‐Fidelity DNA Polymerase and dNTP’s,
both obtained from New England Biolabs (Ipswich, MA). Further
chemicals and reagents were purchased from standard resources and
are of highest purity.
2.2 | Bacterial strains and cultivation
All cloning experiments were performed with E. coli strain TOP10
(Invitrogen). Protein synthesis and whole‐cell biotransformation
were carried out in the E. coli strain C43(DE3) as described in
(Miroux & Walker, 1996). Transformed cells were stored as glycerol
stock with a 1:1 mixture of an overnight culture and glycerol (80%)
at −80°C.
2.3 | Plasmid construction and mutagenesis
2.3.1 | CYP21A2 and CPR−27 expression
The bovine CYP21A2 [UniProt ID: P00191; PDB code: 3QZ1] and
CPR−27 [UniProt ID: Q3SYT8] were expressed in C43(DE) while the
latter is an N‐terminally truncated version with a C‐terminal
3‐glycine‐6‐histidine tag as described (Neunzig et al., 2014). The
truncation of 27 amino acids at the N‐terminus enables high‐yield
expression of a soluble catalytically active CPR. The cloning and
generation of the vector p21b_bRED(−27) was performed as
described in (Brixius‐Anderko et al., 2015; Neunzig et al., 2017)
(Figure 1a).
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2.3.2 | Cytochrome b5 and GroEL, GroES
chaperonins
The vector pREP4‐groESL_cytb5 (Figure 1b) was generated using the
pREP4‐groESL backbone (Cole, 1996). For cloning of the bovine
cytochrome b5 [UniProt ID: P00171], the expression cassette SmaI‐
PT7mod‐cytochrome b5‐TT7mod‐SalI was amplified via PCR using the
template previously described (Klymiuk et al., 2017) and primers
listed in Table S1. The T7 promoter sequence was modified (PT7mod),
to reduce the cytochrome b5 expression level. Hence, adenine was
substituted into thymine in position −6 of the T7 sequence as
proposed by Ikeda, Ligman, and Warshamana (1992). Following, the
digested amplicon was inserted into SmaI and SalI treated pREP4‐
groESL via ligation.
2.3.3 | Site‐directed mutagenesis in M210 of
CYP21A2
p21b_bRED(−27) served as a template for a Quik change® mutagen-
esis changing position M210 of the bovine CYP21A2 sequence. For
this, Pfu polymerase was used and mutagenesis was performed
according to manual instructions from Agilent Technologies (Santa
Clara, CA). All utilized primers are listed in Table S1.
2.4 | Purification of CYP21A2, cytochrome b5, and
CPR−27 and in vitro conversion of medrane
Expression and purification of the bovine proteins CYP21A2, CPR−27,
and cytochrome b5 were performed as described before (Brixius‐
Anderko et al., 2015; Neunzig et al., 2014; Schiffer et al., 2016).
Aliquots were stored at −80°C until used. Protein concentration of
bCPR−27 was calculated using a molar extinction coefficient
ɛ585= 2.4mM
−1·cm−1 (Vermillion, Janice, & Coon, 1978). The con-
centration of bovine cytochrome b5 was determined using a
difference extinction coefficient of 185mM−1·cm−1 for the absor-
bance change at 424–409 nm (Mulrooney & Waskell, 2000).
CYP21A2 concentration was determined by performing difference
spectroscopy according to Omura and Sato using a molar extinction
coefficient of ɛ448= 91mM
−1·cm−1 (Omura & Sato, 1964). The
determination of reaction velocity dependent on enzyme ratio were
performed using the purified enzymes in a reconstituted in vitro
system. The reaction was carried out in 250 µl reaction buffer
containing potassium phosphate buffer (KPi buffer) [50mM K2HPO4/
KH2PO4; pH 7.4], 1 mM MgCl2, 5 mM glucose‐6‐phosphate and 1 U
glucose‐6‐phosphate dehydrogenase. Purified bCYP21 A2 (0.5 µM)
and varying concentrations of the CPR−27, cytochrome b5 and
medrane were added to the reaction buffer. The reaction was
started by application of 500 µM NADPH into the prewarmed
reaction mixture, followed by incubation at 37°C for a defined time.
The reaction was stopped by addition of 250 µl of chloroform.
2.5 | Steroid quantification by reverse‐phase
high‐performance liquid chromatography (RP‐HPLC)
For product quantification via RP‐HPLC, the samples were extracted
twice with double volumes of chloroform. The organic solvent was
evaporated and the remaining steroids were suspended in 50%
acetonitrile and separated on a Jasco reverse phase HPLC system of
the LV2000 and LV900 series using a reverse‐phase ec MN NucleoDur
C18 (4.0 × 125 mm; Macherey‐Nagel, Betlehem, PA). The column was
kept at an oven temperature of 40°C. For measurements of the samples
F IGURE 1 Vector maps containing genes for CYP21A2, CPR, cytochrome b5, and chaperonins. Restriction enzyme cleaving sites are
depicted in red with corresponding positions in the respective plasmid. (a) Vector map of bicistronic p21b_bRED(− 27) containing the genes of
the bovine CYP21A2 and N‐terminally truncated bovine CPR (CPR−27) with the corresponding ribosome binding sites (RBS). Expression of these
proteins is regulated by the T7 promoter. The plasmid contains the gene for ampicillin resistance (AmpR) and a pBR322 origin of replication
(ori). (b) Vector map of the plasmid pREP‐groESL_cytb5, a modified derivative of pREP4‐groESL (Cole, 1996) containing the additional gene of
cytochrome b5 with corresponding RBS under control of a modified T7 promoter (T7*) with decreased induction strength (Ikeda et al., 1992)
and the gene for kanamycin resistance (KanR)
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an acetonitrile/water gradient was applied with a flow rate of 0.8ml/
min and absorbance of the substances was detected at a wavelength of
240 nm (Solution A: 50% ACN; Solution B: 100% ACN; 0–8min: 100%
A; 8–10min: 10% A; 10–10.1min 100% A, 10.1–15min 100% A). The
retention times of medrane (3.2min) and premedrol (2.2min) were
verified with the respective standards. The relative peak area of each
substance was used for calculation of the conversion rates and product
concentration.
2.6 | Protein expression and whole‐cell biocatalysis
Expression of CYP21A2 and redox partners was performed by
inoculation of LB medium with glycerol stocks from transformed
C43(DE3) E. coli cells with the vectors p21b_bRED(−27) (Figure 1a)
or p21b_ArEt (Brixius‐Anderko et al., 2015) and pGro12 (Nishihara,
Kanemori, Kitagawa, & Yura, 1998) or pREP‐groESL_b5 (Figure 1b).
The seed culture was incubated at 37°C overnight. The main culture
was generated in 300ml baffled flasks by inoculation of 30ml of
terrific broth (TB) medium containing the respective antibiotics
(100 µg/ml ampicillin and 50 µg/ml kanamycin) inoculated with the
seed culture using a ratio of 1:100. When the OD600 nm reached 0.5,
the protein production was induced by the addition of 4 g L‐1
arabinose, 1 mM isopropyl‐β‐D‐thiogalactoside (IPTG) and 1mM
δ‐aminolevulinic acid. The temperature was reduced to 30°C and
the expression was performed for 24 hr at 150 rpm. After the
expression period, the cells were harvested by centrifugation
(2500 g, RT, 15min) and washed with 50mM KPi. After the second
centrifugation, the pellet was suspended in 50mM KPi adjusting cell
densities of 24–96 g wet cell weight (gwcw)/L. The biotransformations
were performed in 100ml baffled flasks containing 10ml of the
culture unless otherwise stated. Polymyxin B (32.5 µg/ml) was added
for cell permeabilization providing an improved substrate uptake
(Janocha & Bernhardt, 2013). Biotransformations using batch
cultivation were performed by the addition of 1.2 or 4.8 mM
medrane and 2% or 8% (vol/vol) glycerol. Fed‐batch fermentation
was carried out by adding 1.2 mM medrane and 2% (vol/vol) glycerol,
which was repeated for three times in 2 hr periods. Medrane
conversions were performed at 30°C and 150 rpm for a defined
time. The steroid substrate was dissolved in dimethyl sulfoxide,
which did not exceed 4.8% in conversion cultures. The reaction was
stopped by the addition of the double volume of chloroform.
2.7 | Computational methods
The crystal structure of the bovine CYP21 (PDB 3QZ1) was used as a
receptor for docking into the wild‐type, whereas the M210V mutant
was constructed using the SWISS pdb viewer (version 4.0.1) (Guex &
Peitsch, 1997). For the necessary preparation steps before docking
AutoDock Tools (Windows version 1.5.6r3) was used (Sanner, 1999).
AMBER charges were assigned to the amino acids of the protein part
and Gasteiger‐Marsili charges were computed for the heme cofactor.
To account for its oxidation state, the partial charges were adjusted to
0.400e on the iron atom and ‒0.348e to each of its ligating nitrogen
atoms, respectively. The rectangular grid box (56 × 50 × 64) was
centered around residue 210 To capture all conceivable binding
positions of the ligands in this region. The grid spacing was set to the
default value of 0.375 Å. Medrane and 17α‐hydroxyprogesterone
(17OHP) were constructed manually and energetically optimized using
the MM+ force field parameters as implemented in HYPERCHEM
(HYPERCHEM, Version 6.02, Hypercube Inc., Gainsville, FL). Atom
types and Gasteiger‐Marsili charges for use in AutoDock (version 4.2)
(Huey, Morris, Olson, & Goodsell, 2007; Morris et al., 1998) were
computed with in‐house PERL scripts. During docking all rotatable
bonds of the ligands were treated as flexible, whereas the protein part
was kept rigid. A total of 250 runs of the Lamarckian Genetic
Algorithm for each ligand were carried out, otherwise default
parameters of AutoDock were applied. Hydrophobicity profiles of
the full‐length and truncated bCPR were determined and compared
using the ExPASy online tool Protscale (Gasteiger et al., 2005) based
on the amino acid scale of Kyte and Doolittle (1982).
3 | RESULTS AND DISCUSSION
3.1 | In vivo effect of the N‐terminal CPR
truncation on premedrol formation in the E. coli
whole‐cell system
To enhance the previously established whole‐cell system in E. coli
C43(DE3) (Brixius‐Anderko et al., 2015), we considered different
aspects frequently limiting the efficiency of whole‐cell biotransfor-
mations. The hydroxylating activity of bovine CYP21A2 depends on
the coexistence of a suitable redox partner that mediates the
transfer of two electrons from NADPH+ to CYP21A2. This event
enables the enzymatic regioselective oxidation of medrane in C21
resulting in premedrol. Since an optimal electron supply is allocated
to be an important factor in limiting the conversion yield of P450
mediated systems, we sought to optimize this by substitution of the
coexpressed redox partner in the E. coli whole‐cell system. Therefore,
we modified the membrane‐bound microsomal bovine CPR, which is
the naturally occurring redox partner of bovine CYP21A2. According
to a previous study, the N‐terminal truncation of 27 amino acids
(−27) of the human CPR led to an improved solubility and higher
protein concentrations without affecting the enzyme’s activity in a
recombinant E. coli system (Sandee & Miller, 2011). For electron
transfer, positively charged residues on the proximal site of
CYP21A2 are interacting with acidic residues on the CPR surface
(Hlavica, Schulze, & Lewis, 2003; Shen, Porter, Wilson, & Kasper,
1989). Since the removal of 27 N‐terminal amino acids did not affect
catalytic activity (Sandee & Miller, 2011), the binding sites should be
unaffected. To this end, we generated a modified version of the
plasmid p21b_bRED (Brixius‐Anderko et al., 2015), harboring the
encoding sequence of bCPR−27. The truncated protein‐enhanced
medrane conversion in whole‐cell biotransformations by about 19%
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compared with the reported arh1/etpfd based redox system resulting
in 196.8 ± 24.9 mg·L−1·d−1 although statistical significance cannot be
assured (Figure 2). The presented premedrol production here did not
exceed 320 mg L‐1 as observed by Brixius‐Anderko et al. using arh1/
etpfd, since the latter yield was obtained by multiple addition of lower
substrate concentrations summed up to 1mM. However, comparing
premedrol production obtained by non‐successive substrate addition,
using the bCPR−27 increased the premedrol production 2.4‐fold
compared with premedrol production supported byWT CPR (Brixius‐
Anderko et al., 2015).
This difference in efficiency is due to the membrane‐bound
nature of the WT microsomal CPR which makes it difficult to
be overexpressed in a recombinant bacterial system. The removal of
the N‐terminal membrane‐binding domain putatively increased the
protein’s solubility, as this region is described to be hydrophobic in
rat (Gilep, Guryev, Usanov, & Estabrook, 2001), yeast (Venkateswar-
lu, Lamb, Kelly, Manning, & Kelly, 1998), human (Migita, Togashi,
Minakawa, Zhang, & Yoshida, 2005) and rabbit (Masters, 2005) CPR.
Additionally, in silico determination of hydrophobicity profiles and
average hydrophobicity indices of the bovine CPR sequence revealed
that the truncation of the N‐terminus decreased hydrophobicity of
the protein by 2.7%. This could result in increased stability and,
therefore, higher expression level in the recombinant host. With this,
the excessive accumulation and degradation of hydrophobic proteins
in the cytoplasm is prevented. Consequently, this facilitated the
presence of higher quantities of catalytically active protein. Addi-
tional in vitro experiments using different ratios of P450:CPR
revealed that the increase of CPR up to 1:4 leads to an increase in
reaction velocity (Figures S1 and 3) forming premedrol. Based on this
observation, bCPR−27 was consecutively used for all subsequent
experiments.
3.2 | In vitro effect of cytochrome b5 on premedrol
formation
As shown before by using a truncated CPR version, the efficiency of
electron transfer is one of several limiting factors on whole‐cell
medrane conversions in recombinant E. coli (Figure 2). Thus, we
sought to introduce a putatively supporting protein that is able to
interact with the CPR and/or CYP21A2. In microsomes, cytochrome
b5 is colocated with CYP21A2 and CPR and has previously been
shown to support several individual P450s in their reaction
efficiency, for instance, CYP3A4, CYP2B4 and CYP17A1 (Bart &
Scott, 2017; Bridges et al., 1998; Gilep et al., 2001; Katagiri, Kagawa,
& Waterman, 1995). However, the supportive effect is dependent on
the individual P450 isoform as well as the corresponding redox
partner and the molar ratio of the present enzymes (Imai & Sato,
1977; Lu, West, Vore, Ryan, & Levin, 1974; Morgan & Coon, 1984;
Schenkman, Jansson, & Robie‐Suh, 1976).
The mechanism of cytochrome b5 action is hypothesized as
follows: (a) allosteric activation of P450 supporting the correct
positioning towards CPR (Miller, 2005), (b) cytochrome b5 acts as an
electron transfer intermediate between the reductase and P450s.
Whereas the CPR transfers the first electron with high efficiency,
cytochrome b5 provides the rate‐limiting input of the second electron
to P450 (Schenkman & Jansson, 2003), (c) complexation of
cytochrome b5 to P450 leading to a stabilization of the oxycyto-
chrome P450 complex. In this way, cytochrome b5 can provide a
faster transfer of the second electron than the formation and release
of a superoxide anion. The three suggested mechanisms allow the
F IGURE 2 CYP21A2‐mediated whole‐cell conversion of medrane
in dependence on the redox partners (arh1/etpfd; bCPR−27). The
24 hr expression took place in TB medium after induction with 1mM
IPTG, δ‐ALA, and 0.4% arabinose. The reactions were carried out in
30ml of KPi (pH 7.4), containing 30 µg/ml polymyxin B, 2% glycerol,
1 mM medrane, and 24 gwcw/L of recombinant Escherichia coli cells
for 24 hr. Extracted steroids were quantified via RP‐HPLC. Values
represent the mean of three conversion experiments. Error bars
indicate respective standard deviations. IPTG, isopropyl‐β‐D‐
thiogalactoside; RP‐HPLC, reverse‐phase high‐performance liquid
chromatography; δ‐ALA, δ‐aminolevulinic acid
F IGURE 3 Time‐dependent in vitro conversion of medrane to its
21‐hydroxylated product, premedrol, in dependence on the
CYP21A2:CPR:cytochrome b5 ratio. The in vitro conversions of
100 µM medrane were performed utilizing purified bCYP21A2,
bCPR−27 and cytochrome b5 in KPi buffer. Independent samples were
measured within the linear range (3, 5, 10, and 30min) via RP‐HPLC.
Error bars indicate the respective standard deviation. b5:
cytochrome b5; CPR, CPR−27; P450, CYP21A2; RP‐HPLC, reverse‐
phase high‐performance liquid chromatography
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increase of product formation without influencing NADPH consump-
tion (Gorsky & Coon, 1986; Gruenke, Konopka, Cadieu, & Waskell,
1995). To investigate the effect of cytochrome b5 on CYP21A2
activity, we performed in vitro conversions of medrane using the
purified bovine enzymes of CYP21A2, bCPR−27 and cytochrome b5
(Table S2) at varying ratios from 1:4:0 to 1:4:8 (Figure 3). The optimal
P450:CPR ratio was previously determined to be 1:4, as shown in
Figure S1. At a P450:CPR:cytochrome b5 ratio of 1:0:1 no product
was formed highlighting the mandatory role of CPR for CYP21A2
activity which increased up to 1.25 µM premedrol/min at a ratio of
1:4:0 (Figure 3). We observed that cytochrome b5 has a supporting
effect on product formation, which is increased at least by 90% at a
ratio of 1:4:0.5 compared with 1:4:0 and did not alter considerably at
higher P450:bCPR−27:cytochrome b5 ratios (Figure 3). The lack of
premedrol production at ratio 1:0:1 confirmed the above‐stated
hypothesis that the electron transfer, at least the transfer of the first
electron, is exclusively mediated by CPR and cannot be replaced by
cytochrome b5 (Miller, 2005; Schenkman & Jansson, 2003). The
enhancing effect of the cytochrome b5 at ratios of 1:4:0.5 and above
shows that despite the removal of the first 27 amino acids of the CPR
protein sequence, interaction between both, CPR and cytochrome b5,
still is possible resulting in a higher reaction velocity. With regard to
the elevating effect of cytochrome b5 on the CYP21A2 related
biotransformation, hypotheses (a)–(c) are conceivable in this context.
By contrast, a previous study described an inhibitory effect of
cytochrome b5 on the CYP21A2 activity in vitro (Wang et al., 2017).
The opposite effect demonstrated there may, on one hand, be due to
the use of enzymes from different sources. Whereas in our
experiments all enzymes originate exclusively from the bovine
species, in those experiments human CYP21A2, cytochrome b5 and
rat CPR were used. Moreover, different substrates were investigated
(medrane and progesterone, respectively), which could affect the
influence of cytochrome b5 on the performance of P450 (Bart &
Scott, 2017). Finally, in the experiments described by Wang et al.
(2017), excessive concentrations of cytochrome b5 (1:300) were
used, which may lead to the contrary effect as observed in our
studies, since we did not exceed a P450 to cytochrome b5 ratio
of 1:8.
3.3 | Protein engineering of bCYP21A2 via
site‐directed mutagenesis and in vivo screening
Another possible limiting factor in biotransformations is steric
hindrance of the substrate access into the active site, preventing
substrate‐uptake or product release. Compared with the natural
CYP21A2 substrate 17α‐hydroxyprogesterone (17OHP) (Figures 4a
and 4c) medrane possesses an additional methyl group in C6 and a
hydroxy group in C11 (Figures 4b and 4d). Hence, modification of the
substrate access channel could lead to higher efficiency in medrane
F IGURE 4 Scheme of the CYP21A2‐catalyzed C21‐hydroxylation and structure of the wild type (WT) CYP21A2 substrate access channel in
the presence of 17α‐hydroxyprogesterone (17OHP). (a) The natural substrate 17OHP is hydroxylated by CYP21A2 yielding 11‐deoxycortisol. (b)
The synthetic steroid medrane is hydroxylated at position C21 producing premedrol. Compared to 17OHP, medrane possesses an additional
hydroxy group at C11 and a methyl group at C6 as depicted in red. (c, d) Top view on the CYP21A2 substrate access channel illustrating the
location of methionine (position 210, sulfur colored in yellow) and the ligand. (c) 17OHP as being present in the X‐ray protein structure of bovine
CYP21A2 (PDB: 3QZ1 [marine sticks] (Zhao et al., 2012). (d) Obtained docking position of medrane (green sticks). Oxygen atoms of the steroidal
structure are depicted in red, the prosthetic heme group in pink, and its iron atom as sphere [Color figure can be viewed at wileyonlinelibrary.com]
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conversion. According to Zhao et al. (2012), the methionine in
position 210 of bCYP21A2 is part of the distal 17OHP‐binding region
which interacts with the substrate within 4 Å and is located at the
substrate access channel (Figure 4c). To enhance substrate access to
the active site, we thus examined the impact of steric effects in
product formation in vivo. To this end, we performed site‐directed
mutagenesis of M210 by introducing other hydrophobic residues of
different size (valine, glycine, alanine, isoleucine and phenylalanine).
Indeed, substitution with the smaller valine yielded a 1.3‐fold
increase in premedrol formation (Figure 5a), resulting in
255 ± 20mg·L−1·48 hr−1 (Figure 5b), whereas the introduction of
smaller residues into position M210 produced premedrol levels not
different from that of the WT (Figure 5a). We assume that steric and
hydrophobic effects play a role in this context. Since valine is a more
hydrophobic residue than methionine (Eisenberg, 1984; Kyte and
Doolittle, 1982), hydrophobic interactions could be implicated to
allow correct substrate orientation and faster guidance towards the
catalytically active heme. Our docking results showed energetically
preferred binding positions of both medrane and 17OHP in the same
region as the ligand in the crystal structure (3QZ1), considering its
limited resolution of 3 Å (see Figures 4c and 4d). Interestingly, the
obtained docking conformations in the M210V mutant were identical
to those in the wild type (data not shown). However, since residue
210 is not in direct contact with the ligands, the introduction of a
smaller side chain (valine) obviously does not affect their binding
position. Nevertheless, it is likely that conformational changes of
the protein go along with the diffusion of the ligands further to the
active site, which, however, cannot be elucidated by docking.
Therefore, we assume that the smaller side chain in position 210
affects the dynamics of substrate access indirectly, for example by
altered enzyme stability or expression level. However, it cannot be
ruled out that the mutation may facilitates the substrate’s access by
conformational changes of the protein. Unfortunately, experiments
analyzing modifications of the active site (M197 with saturation
mutagenesis) or the surface (L442A and L224R) of CYP21A2 for
altered solubility did not produce any improved variants for
premedrol production (data not shown).
3.4 | Combinatorial application of developed
strategies on whole‐cell biotransformation of
medrane
Although the effect of CPR truncation on premedrol production and
CYP21A2 mutagenesis has been demonstrated in the E. coli whole‐
cell system, the effects of cytochrome b5 copresence were so far
shown only in vitro. This encouraged us to create a functional in vivo
whole‐cell system that combines the three optimization strategies.
To keep the number of expression vectors to a limit of two, we
created a vector containing the genes for the chaperonins GroES/EL
and cytochrome b5. For this purpose, we modified the vector pREP4‐
groESL (Cole, 1996) and introduced the gene for cytochrome b5
under the control of a modified T7 promoter. As the P450:CPR: b5
ratio 1:4:0.5 is sufficient to have an elevating impact on product
formation in vitro (Figure 3) we introduced a point mutation into the
T7 promoter according to Ikeda et al. (1992). This modification leads
to a residual promoter activity of 13%, which prevents excessive
cytochrome b5 production and thus maintains efficient coexpression
of bCPR−27 and CYP21A2. E. coli C43(DE3) was cotransformed with
the WT CYP21A2 (p21b_bRED(−27)) or modified CYP21A2
F IGURE 5 In vivo conversion of medrane dependent on replacements in position M210 of bCYP21A2. (a) Relative premedrol production
standardized to the WT (M210). Premedrol concentrations were analyzed via RP‐HPLC after a conversion period of 24 hr. (b) Absolute
premedrol concentration dependent on the conversion time. The 24 hr expression period took place in TB medium after induction with 1mM
IPTG, δ‐ALA, and 0.4% arabinose. The reactions were carried out in 30ml of KPi (pH 7.4) containing 30 µg/ml polymyxin B, 2% glycerol, 1.2 mM
medrane, and 24 gwcw/L of recombinant Escherichia coli cells for 24 hr. Extracted steroids were quantified via RP‐HPLC. Values represent the
percentage mean of three conversion experiments. Error bars indicate the respective standard deviation. Values were normalized on premedrol
productions of the WT. IPTG, isopropyl‐β‐D‐thiogalactoside; RP‐HPLC, reverse‐phase high‐performance liquid chromatography; TB, terrific
broth; WT, wild type; δ‐ALA, δ‐aminolevulinic acid [Color figure can be viewed at wileyonlinelibrary.com]
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containing vector (p21b_M210V_bRED(−27)) and with the chaper-
onin vector (pGro12) or chaperonins and cytochrome b5 containing
vector (pREP4‐groESL_cytb5), respectively (Figure 1). Biotransforma-
tion was performed by adding 4.8mM medrane (Figure 6, bright
columns) and 8% (vol/vol) glycerol. In batch cultures (Figure 6, bright
columns) the coexpression of cytochrome b5 with WT CYP21A2
showed an elevating effect on premedrol production by 15%
compared with cultures solely expressing WT CYP21A2. The
substitution M210V in CYP21A2 yielded 404 ± 28mg·L−1·d−1, corre-
sponding to a 25% increased product formation compared with WT
CYP21A2, which is in good agreement with the observations of the
mutant screening shown above (Figure 5). The additional coexpres-
sion of cytochrome b5 slightly increased premedrol formation by
further 13%, summing up to 41% compared with WT CYP21A2
without cytochrome b5 under batch‐cultivation conditions. To
investigate whether a possible substrate inhibition could be a
bottleneck of the process encountered with high initial substrate
concentrations, we changed the protocol from batch‐ into fed‐batch
cultivation. To this end, we applied 1.2mM of the steroidal substrate
medrane together with 2% glycerol in four consecutive feeding steps,
every 2 hr (Figure 6, dark columns). Indeed, the successive addition of
the substrates, medrane and glycerol, had an increasing effect on
final premedrol concentrations as well as on the respective
conversion yields. The latter was enhanced by a maximum of 16%
(WT CYP21A2 with coexpressed cytochrome b5) when using fed‐
batch cultivation in comparison to the batch method.
The fed‐batch method led to substantially higher product
concentrations for both, the CYP21A2 WT and M210 mutant
showing an enhancement by 46% and 43%, respectively, compared
with respective premedrol concentrations resulted from batch
cultivation (Figure 6, bright columns). This resulted in concentrations
of 472 ± 34 (WT) and 578 ± 59mg·L−1·d−1 (M210V) (Figure 6, dark
columns). The enhancing effect of the amino acid replacement
M210V in CYP21A2 is reflected by an improvement of 22% in
premedrol productivity in fed‐batch cultivation, compared with the
WT CYP21A2. This improvement corresponds to a final product
concentration of 578 ± 59mg·L−1·d−1. However, the enhancing effect
of the mutation M210V seemed to be limited to 4%
(691 ± 104mg·L−1·d−1), when cytochrome b5 is coexpressed com-
pared with WT CYP21A2 coexpressed with cytochrome b5
(664 ± 35mg·L−1·d−1). The premedrol production is leveled off at
691 ± 104mg·L−1·d−1. This indicates that there are still other aspects,
limiting the process such as restricted substrate uptake or product
release. Cultures coexpressing cytochrome b5 show highest diver-
gence between batch‐ and fed‐batch induced premedrol productivity
which correspond to an increase by 79% and 51% of the WT and
M210V variant, respectively, compared with the respective batch
induced premedrol productivity. The improved method led to final
space‐time yields of 665 ± 35 and 691 ± 104mg·L−1·d−1, respectively.
In fed‐batch cultivation the coexpression of cytochrome b5 results in
an elevation of final premedrol concentrations by 40% when WT
CYP21A2 is used and by 19% when mutant M210V is applied
(compared with the respective fed‐batch cultivation values without
cytochrome b5 coexpression). The latter reflects the maximum
productivity and conversion yield obtained here by the optimized
process.
Taken together, we showed that by successive substrate feeding
we reduced inhibition encountered with high initial substrate
concentrations. This effect was also observed under conditions,
where the conversion yield decreases asymptotically with increasing
substrate concentrations indicating a substrate‐mediated inhibition
of CYP21A2 (Figure S2). Lin et al. showed the same phenomenon for
several P450 isoforms, and, thus, proposed a two‐site model for
understanding dose‐depending substrate inhibition in P450‐
catalyzed reactions. They hypothesized that the substrate has high
affinity to the active site and lower affinity to a second binding site,
which is occupied at extensive concentrations of the substrate (Lin
et al., 2001). This model can be helpful to describe the higher
productivity by feeding experiments, where substrate concentrations
are kept low due to continuous substrate consumption. In vivo, this
mechanism could be used for a natural regulation process, since
steroid metabolism is a sensitive, fine‐tuned physiological system.
Especially the activity of CYP21A2 is needed to be regulated for
example by feedback‐responses, as the C21 hydroxylation results in
activation of the steroids to act as highly potent ligands of the
glucocorticoid or MR (Attardi et al., 2007; Boland, 1961). Further, we
F IGURE 6 CYP21A2‐mediated whole‐cell conversion of medrane
dependent on the CYP21A2 variant (WT or M210V) and the
presence of cytochrome b5 (Cyt b5). The 24 hr expression period took
place in TB medium after induction with 1mM IPTG, δ‐ALA and 0.4%
arabinose. The reactions were carried out in 10ml of KPi buffer (pH
7.4) for 24 hr, containing 32.5 µg/ml polymyxin B, 2% glycerol and
96 gwcw/L of recombinant Escherichia coli cells. 4.8 mM of medrane
was either added at the beginning of the conversion period (no
feeding, bright columns) or stepwise in 2‐hr time slots each with
1.2 mM medrane (t0‐t6) and 2% glycerol (t2‐t6) (feeding, dark
columns). Extracted steroids were quantified via RP‐HPLC. Values
represent the mean of three conversion experiments. Error bars
indicate respective standard deviations. IPTG, isopropyl‐β‐D‐
thiogalactoside; RP‐HPLC, reverse‐phase high‐performance liquid
chromatography; TB, terrific broth; δ‐ALA, δ‐aminolevulinic acid
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showed that the enhancing effects of the M210V mutation and
cytochrome b5 on CYP21A2 activity are recognizable more clearly
under the conditions of fed‐batch cultivation. Thus, we assume that
the inhibitory effect, which is related to a high substrate concentra-
tion is a major limitation of the process. Further optimization to
exploit the complete catalytic potential could be realized by
controlled fermentation in an automated bioreactor, that allows
continuous titration of the substrate, which is ideally matched on
residual substrate concentration within the culture.
4 | CONCLUSION
We successfully optimized the CYP21A2‐based whole‐cell system in E.
coli. The application of a truncated CPR and coexpression of cytochrome
b5 led to increased efficiency of premedrol formation putatively based on
an improved electron supply or allosteric interaction (Figure 7). The
amino acid replacement M210V located in the substrate access channel
caused a slightly increased product formation. The visibility of the
supportive optimizations was limited by single‐step substrate application,
which we finally uncovered by successive substrate feeding. Applying the
enhanced fed‐batch protocol together with the use of bCPR−27 and
CYP21A2_M210V as well as the coexpression of cytochrome b5 enabled
us to produce up to 691mg·L−1·d−1 premedrol within a biotechnological
E. coli based whole‐cell systemwhich is a more than a 100% improvement
compared with our previously reported system under similar conditions
(Brixius‐Anderko et al., 2015). This is a big step forward towards
application of this system in an industrial process for the sustainable
production of the methylprednisolone‐precursor premedrol.
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